nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—PTGS2—amyotrophic lateral sclerosis	0.436	1	CbGaD
Naproxen—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.232	1	CbGbCtD
Naproxen—Subdural haematoma—Riluzole—amyotrophic lateral sclerosis	0.00991	0.0348	CcSEcCtD
Naproxen—Skin mass—Riluzole—amyotrophic lateral sclerosis	0.0067	0.0236	CcSEcCtD
Naproxen—Nephritis—Riluzole—amyotrophic lateral sclerosis	0.00608	0.0214	CcSEcCtD
Naproxen—Pyelonephritis—Riluzole—amyotrophic lateral sclerosis	0.00546	0.0192	CcSEcCtD
Naproxen—Bundle branch block—Riluzole—amyotrophic lateral sclerosis	0.00412	0.0145	CcSEcCtD
Naproxen—Renal pain—Riluzole—amyotrophic lateral sclerosis	0.00395	0.0139	CcSEcCtD
Naproxen—Urine abnormality—Riluzole—amyotrophic lateral sclerosis	0.00375	0.0132	CcSEcCtD
Naproxen—Cholecystitis—Riluzole—amyotrophic lateral sclerosis	0.00362	0.0127	CcSEcCtD
Naproxen—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00357	0.0126	CcSEcCtD
Naproxen—Urine analysis abnormal—Riluzole—amyotrophic lateral sclerosis	0.00353	0.0124	CcSEcCtD
Naproxen—Enlargement abdomen—Riluzole—amyotrophic lateral sclerosis	0.00345	0.0121	CcSEcCtD
Naproxen—Myasthenia—Riluzole—amyotrophic lateral sclerosis	0.0033	0.0116	CcSEcCtD
Naproxen—Respiratory distress—Riluzole—amyotrophic lateral sclerosis	0.00327	0.0115	CcSEcCtD
Naproxen—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.0032	0.0113	CcSEcCtD
Naproxen—Calculus of kidney—Riluzole—amyotrophic lateral sclerosis	0.00317	0.0111	CcSEcCtD
Naproxen—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00299	0.0105	CcSEcCtD
Naproxen—Lung disorder—Riluzole—amyotrophic lateral sclerosis	0.00293	0.0103	CcSEcCtD
Naproxen—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00291	0.0102	CcSEcCtD
Naproxen—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00288	0.0101	CcSEcCtD
Naproxen—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00978	CcSEcCtD
Naproxen—Respiratory depression—Riluzole—amyotrophic lateral sclerosis	0.00276	0.0097	CcSEcCtD
Naproxen—Pulmonary function test decreased—Riluzole—amyotrophic lateral sclerosis	0.00276	0.0097	CcSEcCtD
Naproxen—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00269	0.00946	CcSEcCtD
Naproxen—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00267	0.00938	CcSEcCtD
Naproxen—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00923	CcSEcCtD
Naproxen—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.00258	0.00908	CcSEcCtD
Naproxen—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.00256	0.00901	CcSEcCtD
Naproxen—Apnoea—Riluzole—amyotrophic lateral sclerosis	0.00245	0.00861	CcSEcCtD
Naproxen—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00814	CcSEcCtD
Naproxen—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00808	CcSEcCtD
Naproxen—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00803	CcSEcCtD
Naproxen—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00803	CcSEcCtD
Naproxen—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00227	0.00798	CcSEcCtD
Naproxen—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.00225	0.00792	CcSEcCtD
Naproxen—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00224	0.00787	CcSEcCtD
Naproxen—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.0022	0.00772	CcSEcCtD
Naproxen—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.0022	0.00772	CcSEcCtD
Naproxen—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00767	CcSEcCtD
Naproxen—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00212	0.00744	CcSEcCtD
Naproxen—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.0021	0.00739	CcSEcCtD
Naproxen—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00722	CcSEcCtD
Naproxen—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00203	0.00713	CcSEcCtD
Naproxen—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00705	CcSEcCtD
Naproxen—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.00195	0.00686	CcSEcCtD
Naproxen—Coma—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00667	CcSEcCtD
Naproxen—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00188	0.0066	CcSEcCtD
Naproxen—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00185	0.0065	CcSEcCtD
Naproxen—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00182	0.0064	CcSEcCtD
Naproxen—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00634	CcSEcCtD
Naproxen—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00634	CcSEcCtD
Naproxen—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00621	CcSEcCtD
Naproxen—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00173	0.00609	CcSEcCtD
Naproxen—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00604	CcSEcCtD
Naproxen—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00593	CcSEcCtD
Naproxen—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00593	CcSEcCtD
Naproxen—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00168	0.0059	CcSEcCtD
Naproxen—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00584	CcSEcCtD
Naproxen—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00564	CcSEcCtD
Naproxen—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00562	CcSEcCtD
Naproxen—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00557	CcSEcCtD
Naproxen—Purpura—Riluzole—amyotrophic lateral sclerosis	0.00156	0.0055	CcSEcCtD
Naproxen—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00548	CcSEcCtD
Naproxen—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00543	CcSEcCtD
Naproxen—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00151	0.0053	CcSEcCtD
Naproxen—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00151	0.0053	CcSEcCtD
Naproxen—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00151	0.0053	CcSEcCtD
Naproxen—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00522	CcSEcCtD
Naproxen—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00522	CcSEcCtD
Naproxen—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00504	CcSEcCtD
Naproxen—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00502	CcSEcCtD
Naproxen—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00493	CcSEcCtD
Naproxen—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00489	CcSEcCtD
Naproxen—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00482	CcSEcCtD
Naproxen—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00479	CcSEcCtD
Naproxen—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00469	CcSEcCtD
Naproxen—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00467	CcSEcCtD
Naproxen—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00461	CcSEcCtD
Naproxen—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00458	CcSEcCtD
Naproxen—Influenza—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00458	CcSEcCtD
Naproxen—Asthma—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00458	CcSEcCtD
Naproxen—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00449	CcSEcCtD
Naproxen—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00446	CcSEcCtD
Naproxen—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00441	CcSEcCtD
Naproxen—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00439	CcSEcCtD
Naproxen—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00435	CcSEcCtD
Naproxen—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00428	CcSEcCtD
Naproxen—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00423	CcSEcCtD
Naproxen—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00418	CcSEcCtD
Naproxen—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00414	CcSEcCtD
Naproxen—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00411	CcSEcCtD
Naproxen—Depression—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00407	CcSEcCtD
Naproxen—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00403	CcSEcCtD
Naproxen—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00114	0.004	CcSEcCtD
Naproxen—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00114	0.004	CcSEcCtD
Naproxen—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00398	CcSEcCtD
Naproxen—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00398	CcSEcCtD
Naproxen—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00397	CcSEcCtD
Naproxen—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00392	CcSEcCtD
Naproxen—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00389	CcSEcCtD
Naproxen—Nabumetone—PTGS2—amyotrophic lateral sclerosis	0.00111	0.23	CrCbGaD
Naproxen—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00386	CcSEcCtD
Naproxen—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00385	CcSEcCtD
Naproxen—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00383	CcSEcCtD
Naproxen—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00381	CcSEcCtD
Naproxen—Carprofen—PTGS2—amyotrophic lateral sclerosis	0.00106	0.219	CrCbGaD
Naproxen—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00369	CcSEcCtD
Naproxen—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00368	CcSEcCtD
Naproxen—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00367	CcSEcCtD
Naproxen—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00367	CcSEcCtD
Naproxen—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00365	CcSEcCtD
Naproxen—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00364	CcSEcCtD
Naproxen—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00362	CcSEcCtD
Naproxen—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00361	CcSEcCtD
Naproxen—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00103	0.0036	CcSEcCtD
Naproxen—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00359	CcSEcCtD
Naproxen—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000986	0.00347	CcSEcCtD
Naproxen—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000975	0.00343	CcSEcCtD
Naproxen—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000968	0.0034	CcSEcCtD
Naproxen—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000946	0.00333	CcSEcCtD
Naproxen—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000942	0.00331	CcSEcCtD
Naproxen—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00094	0.0033	CcSEcCtD
Naproxen—Chills—Riluzole—amyotrophic lateral sclerosis	0.000936	0.00329	CcSEcCtD
Naproxen—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000932	0.00328	CcSEcCtD
Naproxen—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000922	0.00324	CcSEcCtD
Naproxen—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000914	0.00321	CcSEcCtD
Naproxen—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000908	0.00319	CcSEcCtD
Naproxen—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000895	0.00315	CcSEcCtD
Naproxen—Tension—Riluzole—amyotrophic lateral sclerosis	0.000891	0.00313	CcSEcCtD
Naproxen—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.000882	0.0031	CcSEcCtD
Naproxen—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000873	0.00307	CcSEcCtD
Naproxen—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000851	0.00299	CcSEcCtD
Naproxen—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000843	0.00296	CcSEcCtD
Naproxen—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000839	0.00295	CcSEcCtD
Naproxen—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00083	0.00292	CcSEcCtD
Naproxen—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000819	0.00288	CcSEcCtD
Naproxen—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000816	0.00287	CcSEcCtD
Naproxen—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000814	0.00286	CcSEcCtD
Naproxen—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000813	0.00286	CcSEcCtD
Naproxen—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000802	0.00282	CcSEcCtD
Naproxen—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000798	0.00281	CcSEcCtD
Naproxen—Cough—Riluzole—amyotrophic lateral sclerosis	0.000792	0.00279	CcSEcCtD
Naproxen—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000787	0.00277	CcSEcCtD
Naproxen—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000784	0.00276	CcSEcCtD
Naproxen—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000773	0.00272	CcSEcCtD
Naproxen—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000773	0.00272	CcSEcCtD
Naproxen—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000773	0.00272	CcSEcCtD
Naproxen—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00077	0.00271	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000768	0.0027	CcSEcCtD
Naproxen—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000764	0.00269	CcSEcCtD
Naproxen—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000756	0.00266	CcSEcCtD
Naproxen—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000747	0.00263	CcSEcCtD
Naproxen—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000741	0.00261	CcSEcCtD
Naproxen—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000741	0.00261	CcSEcCtD
Naproxen—Infection—Riluzole—amyotrophic lateral sclerosis	0.000736	0.00259	CcSEcCtD
Naproxen—Shock—Riluzole—amyotrophic lateral sclerosis	0.000729	0.00256	CcSEcCtD
Naproxen—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000727	0.00255	CcSEcCtD
Naproxen—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000726	0.00255	CcSEcCtD
Naproxen—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000723	0.00254	CcSEcCtD
Naproxen—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00072	0.00253	CcSEcCtD
Naproxen—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000716	0.00252	CcSEcCtD
Naproxen—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000706	0.00248	CcSEcCtD
Naproxen—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000693	0.00243	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000675	0.00237	CcSEcCtD
Naproxen—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00067	0.00236	CcSEcCtD
Naproxen—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000665	0.00234	CcSEcCtD
Naproxen—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000661	0.00232	CcSEcCtD
Naproxen—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000659	0.00232	CcSEcCtD
Naproxen—Suprofen—PTGS2—amyotrophic lateral sclerosis	0.000652	0.135	CrCbGaD
Naproxen—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000652	0.00229	CcSEcCtD
Naproxen—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000644	0.00226	CcSEcCtD
Naproxen—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00064	0.00225	CcSEcCtD
Naproxen—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000639	0.00225	CcSEcCtD
Naproxen—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000634	0.00223	CcSEcCtD
Naproxen—Pain—Riluzole—amyotrophic lateral sclerosis	0.000634	0.00223	CcSEcCtD
Naproxen—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000611	0.00215	CcSEcCtD
Naproxen—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000606	0.00213	CcSEcCtD
Naproxen—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000589	0.00207	CcSEcCtD
Naproxen—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000586	0.00206	CcSEcCtD
Naproxen—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000586	0.00206	CcSEcCtD
Naproxen—Fenoprofen—PTGS2—amyotrophic lateral sclerosis	0.000562	0.117	CrCbGaD
Naproxen—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000546	0.00192	CcSEcCtD
Naproxen—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000532	0.00187	CcSEcCtD
Naproxen—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000524	0.00184	CcSEcCtD
Naproxen—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000507	0.00178	CcSEcCtD
Naproxen—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00049	0.00172	CcSEcCtD
Naproxen—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000471	0.00166	CcSEcCtD
Naproxen—Rash—Riluzole—amyotrophic lateral sclerosis	0.000467	0.00164	CcSEcCtD
Naproxen—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000467	0.00164	CcSEcCtD
Naproxen—Headache—Riluzole—amyotrophic lateral sclerosis	0.000464	0.00163	CcSEcCtD
Naproxen—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00044	0.00155	CcSEcCtD
Naproxen—Indomethacin—PTGS2—amyotrophic lateral sclerosis	0.000415	0.0861	CrCbGaD
Naproxen—Flurbiprofen—PTGS2—amyotrophic lateral sclerosis	0.000367	0.0761	CrCbGaD
Naproxen—Ketoprofen—PTGS2—amyotrophic lateral sclerosis	0.000332	0.0689	CrCbGaD
Naproxen—Ibuprofen—PTGS2—amyotrophic lateral sclerosis	0.000327	0.0678	CrCbGaD
Naproxen—UGT1A1—Metabolism—TPK1—amyotrophic lateral sclerosis	8.95e-05	0.0021	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	8.95e-05	0.0021	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	8.94e-05	0.0021	CbGpPWpGaD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	8.86e-05	0.00208	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—FIG4—amyotrophic lateral sclerosis	8.81e-05	0.00206	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	8.77e-05	0.00206	CbGpPWpGaD
Naproxen—ALB—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	8.76e-05	0.00205	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	8.61e-05	0.00202	CbGpPWpGaD
Naproxen—CYP2C8—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	8.56e-05	0.00201	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	8.5e-05	0.00199	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	8.5e-05	0.00199	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—GSR—amyotrophic lateral sclerosis	8.48e-05	0.00199	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	8.46e-05	0.00198	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	8.43e-05	0.00198	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	8.41e-05	0.00197	CbGpPWpGaD
Naproxen—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	8.33e-05	0.00195	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—VAPA—amyotrophic lateral sclerosis	8.19e-05	0.00192	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	8.18e-05	0.00192	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	8.16e-05	0.00191	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	7.99e-05	0.00187	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	7.99e-05	0.00187	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—DAO—amyotrophic lateral sclerosis	7.96e-05	0.00187	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	7.94e-05	0.00186	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	7.88e-05	0.00185	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	7.72e-05	0.00181	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	7.68e-05	0.0018	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	7.67e-05	0.0018	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.61e-05	0.00178	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	7.58e-05	0.00178	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	7.58e-05	0.00178	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	7.36e-05	0.00173	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	7.32e-05	0.00172	CbGpPWpGaD
Naproxen—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	7.31e-05	0.00171	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—VAPB—amyotrophic lateral sclerosis	7.3e-05	0.00171	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—TPK1—amyotrophic lateral sclerosis	7.3e-05	0.00171	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	7.29e-05	0.00171	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	7.22e-05	0.00169	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—FIG4—amyotrophic lateral sclerosis	7.16e-05	0.00168	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	7.13e-05	0.00167	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	7.12e-05	0.00167	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—IGF1—amyotrophic lateral sclerosis	7.05e-05	0.00165	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CST3—amyotrophic lateral sclerosis	7.02e-05	0.00164	CbGpPWpGaD
Naproxen—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	6.97e-05	0.00163	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—CHAT—amyotrophic lateral sclerosis	6.96e-05	0.00163	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—DAO—amyotrophic lateral sclerosis	6.93e-05	0.00163	CbGpPWpGaD
Naproxen—PTGS2—Disease—TPK1—amyotrophic lateral sclerosis	6.92e-05	0.00162	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	6.89e-05	0.00161	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VCP—amyotrophic lateral sclerosis	6.85e-05	0.0016	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	6.8e-05	0.0016	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	6.73e-05	0.00158	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—amyotrophic lateral sclerosis	6.72e-05	0.00157	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	6.69e-05	0.00157	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—VAPA—amyotrophic lateral sclerosis	6.67e-05	0.00156	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	6.63e-05	0.00155	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—DAO—amyotrophic lateral sclerosis	6.47e-05	0.00152	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	6.39e-05	0.0015	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	6.37e-05	0.00149	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.35e-05	0.00149	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	6.26e-05	0.00147	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.2e-05	0.00145	CbGpPWpGaD
Naproxen—CYP2C8—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.15e-05	0.00144	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	6.07e-05	0.00142	CbGpPWpGaD
Naproxen—CYP2C8—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.07e-05	0.00142	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PLB1—amyotrophic lateral sclerosis	6.04e-05	0.00141	CbGpPWpGaD
Naproxen—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	5.95e-05	0.0014	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	5.89e-05	0.00138	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	5.88e-05	0.00138	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—FIG4—amyotrophic lateral sclerosis	5.83e-05	0.00137	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	5.82e-05	0.00136	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	5.8e-05	0.00136	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—TPK1—amyotrophic lateral sclerosis	5.79e-05	0.00136	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—VAPB—amyotrophic lateral sclerosis	5.79e-05	0.00136	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	5.77e-05	0.00135	CbGpPWpGaD
Naproxen—ALB—Hemostasis—RAB5A—amyotrophic lateral sclerosis	5.64e-05	0.00132	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GSR—amyotrophic lateral sclerosis	5.57e-05	0.00131	CbGpPWpGaD
Naproxen—PTGS2—Disease—VTA1—amyotrophic lateral sclerosis	5.53e-05	0.0013	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PFN1—amyotrophic lateral sclerosis	5.47e-05	0.00128	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	5.42e-05	0.00127	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	5.4e-05	0.00127	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—VAPA—amyotrophic lateral sclerosis	5.3e-05	0.00124	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—DAO—amyotrophic lateral sclerosis	5.28e-05	0.00124	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	5.26e-05	0.00123	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	5.13e-05	0.0012	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CASP9—amyotrophic lateral sclerosis	5.1e-05	0.0012	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	5.01e-05	0.00118	CbGpPWpGaD
Naproxen—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.01e-05	0.00117	CbGpPWpGaD
Naproxen—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.94e-05	0.00116	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.93e-05	0.00115	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	4.91e-05	0.00115	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PLB1—amyotrophic lateral sclerosis	4.9e-05	0.00115	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	4.89e-05	0.00115	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GSR—amyotrophic lateral sclerosis	4.85e-05	0.00114	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	4.72e-05	0.00111	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	4.71e-05	0.00111	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	4.71e-05	0.00111	CbGpPWpGaD
Naproxen—ALB—Metabolism—VAPB—amyotrophic lateral sclerosis	4.69e-05	0.0011	CbGpPWpGaD
Naproxen—ALB—Metabolism—TPK1—amyotrophic lateral sclerosis	4.69e-05	0.0011	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	4.64e-05	0.00109	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—FIG4—amyotrophic lateral sclerosis	4.63e-05	0.00109	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—VEGFA—amyotrophic lateral sclerosis	4.6e-05	0.00108	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	4.6e-05	0.00108	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CHAT—amyotrophic lateral sclerosis	4.57e-05	0.00107	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GSR—amyotrophic lateral sclerosis	4.53e-05	0.00106	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	4.42e-05	0.00104	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.39e-05	0.00103	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—amyotrophic lateral sclerosis	4.39e-05	0.00103	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.37e-05	0.00102	CbGpPWpGaD
Naproxen—AKR1C3—Disease—ERBB4—amyotrophic lateral sclerosis	4.37e-05	0.00102	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.35e-05	0.00102	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	4.34e-05	0.00102	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	4.31e-05	0.00101	CbGpPWpGaD
Naproxen—ALB—Metabolism—VAPA—amyotrophic lateral sclerosis	4.29e-05	0.001	CbGpPWpGaD
Naproxen—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.28e-05	0.001	CbGpPWpGaD
Naproxen—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.22e-05	0.000989	CbGpPWpGaD
Naproxen—PTGS2—Disease—CHMP2B—amyotrophic lateral sclerosis	4.19e-05	0.000982	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—DAO—amyotrophic lateral sclerosis	4.19e-05	0.000982	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	4.15e-05	0.000974	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	4.15e-05	0.000974	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—TP53—amyotrophic lateral sclerosis	4.06e-05	0.000951	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	4.03e-05	0.000946	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.01e-05	0.00094	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4e-05	0.000938	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PLB1—amyotrophic lateral sclerosis	4e-05	0.000937	CbGpPWpGaD
Naproxen—ALB—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.98e-05	0.000934	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	3.98e-05	0.000934	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	3.84e-05	0.000899	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	3.84e-05	0.000899	CbGpPWpGaD
Naproxen—PTGS2—Disease—PLB1—amyotrophic lateral sclerosis	3.79e-05	0.000889	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	3.77e-05	0.000883	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.75e-05	0.000879	CbGpPWpGaD
Naproxen—ALB—Metabolism—FIG4—amyotrophic lateral sclerosis	3.75e-05	0.000878	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.74e-05	0.000877	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	3.72e-05	0.000871	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	3.7e-05	0.000868	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GSR—amyotrophic lateral sclerosis	3.69e-05	0.000865	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.63e-05	0.000852	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.58e-05	0.000839	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.57e-05	0.000838	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	3.51e-05	0.000823	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.44e-05	0.000806	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	3.41e-05	0.000799	CbGpPWpGaD
Naproxen—ALB—Metabolism—DAO—amyotrophic lateral sclerosis	3.39e-05	0.000794	CbGpPWpGaD
Naproxen—PTGS2—Disease—VCP—amyotrophic lateral sclerosis	3.38e-05	0.000792	CbGpPWpGaD
Naproxen—AKR1C3—Disease—APOE—amyotrophic lateral sclerosis	3.38e-05	0.000792	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.36e-05	0.000788	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.34e-05	0.000784	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	3.28e-05	0.000769	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	3.28e-05	0.000769	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.26e-05	0.000765	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PLB1—amyotrophic lateral sclerosis	3.17e-05	0.000744	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	3.15e-05	0.000739	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	3.13e-05	0.000733	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	3.07e-05	0.000719	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.06e-05	0.000717	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.06e-05	0.000717	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CHAT—amyotrophic lateral sclerosis	3.03e-05	0.00071	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	3e-05	0.000703	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSR—amyotrophic lateral sclerosis	2.93e-05	0.000687	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.87e-05	0.000674	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.84e-05	0.000665	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—APOE—amyotrophic lateral sclerosis	2.83e-05	0.000663	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.79e-05	0.000653	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	2.77e-05	0.00065	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.76e-05	0.000648	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.67e-05	0.000625	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	2.64e-05	0.00062	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.62e-05	0.000614	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	2.58e-05	0.000605	CbGpPWpGaD
Naproxen—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	2.57e-05	0.000602	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.54e-05	0.000596	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.49e-05	0.000584	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.46e-05	0.000576	CbGpPWpGaD
Naproxen—PTGS2—Disease—CST3—amyotrophic lateral sclerosis	2.42e-05	0.000568	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.41e-05	0.000564	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	2.38e-05	0.000559	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	2.37e-05	0.000556	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	2.37e-05	0.000556	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	2.37e-05	0.000556	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.37e-05	0.000555	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTGS2—amyotrophic lateral sclerosis	2.31e-05	0.000543	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.26e-05	0.00053	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.19e-05	0.000515	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.17e-05	0.000509	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.16e-05	0.000506	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.14e-05	0.000503	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.14e-05	0.000502	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	2.1e-05	0.000493	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	2.04e-05	0.000479	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2e-05	0.000468	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.97e-05	0.000461	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	1.96e-05	0.000459	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.95e-05	0.000458	CbGpPWpGaD
Naproxen—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	1.95e-05	0.000456	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	1.94e-05	0.000455	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.94e-05	0.000454	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.89e-05	0.000444	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—APOE—amyotrophic lateral sclerosis	1.86e-05	0.000436	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.84e-05	0.00043	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.8e-05	0.000421	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.79e-05	0.000419	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.78e-05	0.000416	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.77e-05	0.000414	CbGpPWpGaD
Naproxen—PTGS2—Disease—CASP9—amyotrophic lateral sclerosis	1.76e-05	0.000413	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.66e-05	0.000389	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.63e-05	0.000382	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—APOE—amyotrophic lateral sclerosis	1.62e-05	0.000379	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.61e-05	0.000378	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	1.59e-05	0.000373	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—APOE—amyotrophic lateral sclerosis	1.51e-05	0.000354	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.51e-05	0.000354	CbGpPWpGaD
Naproxen—PTGS2—Disease—ERBB4—amyotrophic lateral sclerosis	1.51e-05	0.000354	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.5e-05	0.000353	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.5e-05	0.000351	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.45e-05	0.000341	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.42e-05	0.000333	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.36e-05	0.000319	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.29e-05	0.000303	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.28e-05	0.000299	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.27e-05	0.000299	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.24e-05	0.000291	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—APOE—amyotrophic lateral sclerosis	1.23e-05	0.000289	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.22e-05	0.000287	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.22e-05	0.000285	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.19e-05	0.000279	CbGpPWpGaD
Naproxen—PTGS2—Disease—APOE—amyotrophic lateral sclerosis	1.17e-05	0.000274	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.11e-05	0.00026	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.05e-05	0.000247	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.05e-05	0.000247	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.05e-05	0.000245	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.03e-05	0.000243	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.96e-06	0.000233	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—APOE—amyotrophic lateral sclerosis	9.77e-06	0.000229	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.67e-06	0.000227	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.65e-06	0.000226	CbGpPWpGaD
Naproxen—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.61e-06	0.000225	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.56e-06	0.000201	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	8.51e-06	0.0002	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.44e-06	0.000198	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	7.95e-06	0.000186	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	7.95e-06	0.000186	CbGpPWpGaD
Naproxen—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	7.91e-06	0.000185	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.87e-06	0.000184	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.32e-06	0.000172	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.72e-06	0.000158	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	6.47e-06	0.000152	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	5.53e-06	0.00013	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.45e-06	0.000128	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.42e-06	0.000127	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.44e-06	0.000104	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.79e-06	8.89e-05	CbGpPWpGaD
